DK3201230T3 - Canine pd-l1-bindende pd-l1-antistoffer - Google Patents
Canine pd-l1-bindende pd-l1-antistoffer Download PDFInfo
- Publication number
- DK3201230T3 DK3201230T3 DK15771582.2T DK15771582T DK3201230T3 DK 3201230 T3 DK3201230 T3 DK 3201230T3 DK 15771582 T DK15771582 T DK 15771582T DK 3201230 T3 DK3201230 T3 DK 3201230T3
- Authority
- DK
- Denmark
- Prior art keywords
- canine
- antibodies
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057541P | 2014-09-30 | 2014-09-30 | |
| US201562172511P | 2015-06-08 | 2015-06-08 | |
| PCT/EP2015/072324 WO2016050721A1 (en) | 2014-09-30 | 2015-09-29 | Pd-l1 antibodies binding canine pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3201230T3 true DK3201230T3 (da) | 2021-02-15 |
Family
ID=54207505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15771582.2T DK3201230T3 (da) | 2014-09-30 | 2015-09-29 | Canine pd-l1-bindende pd-l1-antistoffer |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10550194B2 (da) |
| EP (1) | EP3201230B1 (da) |
| JP (1) | JP6797111B2 (da) |
| CN (2) | CN107074952B (da) |
| AU (2) | AU2015326996B2 (da) |
| CA (1) | CA2961987A1 (da) |
| DK (1) | DK3201230T3 (da) |
| ES (1) | ES2853823T3 (da) |
| RU (1) | RU2722562C2 (da) |
| WO (1) | WO2016050721A1 (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN106029697B (zh) * | 2013-12-20 | 2021-06-04 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2980087A1 (en) | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| CA3005696A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3481413A4 (en) * | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO2018024237A1 (zh) * | 2016-08-04 | 2018-02-08 | 信达生物制药(苏州)有限公司 | 抗pd-l1纳米抗体及其应用 |
| KR20230125085A (ko) * | 2016-08-15 | 2023-08-28 | 국립대학법인 홋가이도 다이가쿠 | 항pd-l1 항체 |
| US20200181258A1 (en) * | 2016-10-17 | 2020-06-11 | Vetoquinol Sa | Modified antibody constant region |
| JP7036388B2 (ja) * | 2017-03-27 | 2022-03-15 | 国立大学法人北海道大学 | Ｐｄ－ｌ１検出用抗ｐｄ－ｌ１抗体 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| CN111344305B (zh) * | 2017-11-27 | 2022-09-16 | 山东博安生物技术股份有限公司 | 抗pd-l1的抗体及其用途 |
| US20210388053A1 (en) * | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
| CN120904316A (zh) * | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
| CN110194799B (zh) * | 2019-06-03 | 2021-07-23 | 北京希诺谷生物科技有限公司 | 结合犬pd-1的抗犬pd-1抗体 |
| WO2021009188A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies to human and canine ctla-4 |
| CA3145345A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies against canine ctla-4 |
| CN110590959B (zh) * | 2019-09-19 | 2021-01-05 | 北京伟杰信生物科技有限公司 | 重组犬pd-1融合蛋白及其制备方法与应用 |
| JP2023529557A (ja) | 2020-05-04 | 2023-07-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｅｎｐｐ１抗体の阻害 |
| MX2022013840A (es) * | 2020-05-04 | 2023-02-09 | Inhibrx Inc | Polipéptidos de unión a pd-1 canina y usos de los mismos. |
| JP2024530036A (ja) * | 2021-08-06 | 2024-08-14 | ペットメディックス・リミテッド | 抗体Ｆｃバリアント |
| EP4602073A2 (en) * | 2022-11-15 | 2025-08-20 | Purdue Research Foundation | Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof |
| US20240209096A1 (en) | 2022-12-27 | 2024-06-27 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| AU2024210302A1 (en) | 2023-01-20 | 2025-09-04 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| JP2026508149A (ja) * | 2023-02-13 | 2026-03-10 | インターベット インターナショナル ベー． フェー． | イヌｉｌ－１３に対するイヌ抗体 |
| WO2025113570A1 (en) * | 2023-11-29 | 2025-06-05 | Vetigenics, Inc. | Fully canine antibodies and uses thereof |
| CN120137035A (zh) * | 2023-12-06 | 2025-06-13 | 北京伟杰信生物科技有限公司 | 一种抗犬pd-1抗体及其用途 |
| KR20250091367A (ko) * | 2023-12-13 | 2025-06-23 | 주식회사 노드큐어 | 개 pdl-1 항체 및 이의 용도 |
| WO2025128263A1 (en) * | 2023-12-15 | 2025-06-19 | Pharmaessentia Corporation | Anti-pd-1 monoclonal antibody and methods of preparation thereof |
| US12454565B2 (en) | 2024-03-21 | 2025-10-28 | Akston Biosciences Corporation | PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use |
| CN119591713B (zh) * | 2024-12-12 | 2025-10-14 | 扬州大学 | 猫pd-l1单克隆抗体、分泌猫pd-l1单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6703360B2 (en) | 2000-04-07 | 2004-03-09 | Heska Corporation | Compositions and methods related to canine IgG and canine IL-13 receptors |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| BRPI0818287A2 (pt) * | 2007-10-08 | 2015-11-03 | Intrexon Corp | células dendríticas manipuladas e usos para o tratamento do câncer. |
| EP2331579B1 (en) | 2008-09-04 | 2017-07-05 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| AU2013204861B2 (en) * | 2008-09-26 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| EP2411050A4 (en) | 2009-03-25 | 2013-07-17 | Vet Therapeutics Inc | ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| WO2011066342A2 (en) * | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| EP2542258A4 (en) | 2010-03-04 | 2013-08-21 | Vet Therapeutics Inc | ON CD52 MONOCLONAL ANTIBODIES |
| US9616120B2 (en) | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
| GB2504887B (en) | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-Nerve growth factor antibodies and methods of preparing and using the same |
| US9580496B2 (en) | 2011-05-06 | 2017-02-28 | Nexvet Australia Pty Ltd | Therapeutic canine immunoglobulins and methods of using same |
| GB201114858D0 (en) | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| ES2704007T3 (es) | 2011-05-06 | 2019-03-13 | Nexvet Australia Pty Ltd | Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos |
| CA2835094C (en) | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| EP2751139A1 (en) | 2011-08-30 | 2014-07-09 | NVIP Pty Ltd | Caninised tumour necrosis factor antibodies and methods of using the same |
| AU2012328819B2 (en) | 2011-10-26 | 2017-08-03 | Elanco Tiergesundheit Ag | Monoclonal antibodies and methods of use |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CN106029697B (zh) | 2013-12-20 | 2021-06-04 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
| US10280223B2 (en) | 2014-07-09 | 2019-05-07 | Nippon Zenyaku Kogyo Co., Ltd. | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
| PT3177640T (pt) * | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
| US20160129097A1 (en) * | 2014-11-06 | 2016-05-12 | Jeremy Delk | Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit |
-
2015
- 2015-09-29 CN CN201580052709.9A patent/CN107074952B/zh active Active
- 2015-09-29 DK DK15771582.2T patent/DK3201230T3/da active
- 2015-09-29 CA CA2961987A patent/CA2961987A1/en active Pending
- 2015-09-29 US US15/514,920 patent/US10550194B2/en active Active
- 2015-09-29 EP EP15771582.2A patent/EP3201230B1/en active Active
- 2015-09-29 CN CN202110355046.5A patent/CN112851816B/zh active Active
- 2015-09-29 JP JP2017516842A patent/JP6797111B2/ja active Active
- 2015-09-29 AU AU2015326996A patent/AU2015326996B2/en active Active
- 2015-09-29 WO PCT/EP2015/072324 patent/WO2016050721A1/en not_active Ceased
- 2015-09-29 ES ES15771582T patent/ES2853823T3/es active Active
- 2015-09-29 RU RU2017114341A patent/RU2722562C2/ru active
-
2019
- 2019-12-18 US US16/718,729 patent/US11447561B2/en active Active
-
2021
- 2021-08-18 AU AU2021218094A patent/AU2021218094B2/en active Active
-
2022
- 2022-08-15 US US17/819,745 patent/US20220389114A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2722562C2 (ru) | 2020-06-01 |
| RU2017114341A3 (da) | 2019-07-17 |
| CN107074952B (zh) | 2021-04-09 |
| AU2021218094A1 (en) | 2021-09-09 |
| JP6797111B2 (ja) | 2020-12-09 |
| RU2020117210A (ru) | 2020-06-16 |
| US20200109212A1 (en) | 2020-04-09 |
| JP2017534267A (ja) | 2017-11-24 |
| AU2021218094B2 (en) | 2023-04-20 |
| CA2961987A1 (en) | 2016-04-07 |
| AU2015326996A1 (en) | 2017-03-23 |
| WO2016050721A1 (en) | 2016-04-07 |
| US10550194B2 (en) | 2020-02-04 |
| CN112851816B (zh) | 2024-03-08 |
| CN112851816A (zh) | 2021-05-28 |
| US20180237535A1 (en) | 2018-08-23 |
| ES2853823T3 (es) | 2021-09-17 |
| RU2017114341A (ru) | 2018-11-09 |
| EP3201230A1 (en) | 2017-08-09 |
| US20220389114A1 (en) | 2022-12-08 |
| CN107074952A (zh) | 2017-08-18 |
| BR112017006203A2 (pt) | 2018-05-02 |
| EP3201230B1 (en) | 2020-12-23 |
| AU2015326996B2 (en) | 2021-05-20 |
| US11447561B2 (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3201230T3 (da) | Canine pd-l1-bindende pd-l1-antistoffer | |
| IL263834A (en) | Anti-pd-l1 antibodies | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| IL249512B (en) | Antibodies binding axl | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3334824T3 (da) | Pd-1-antistoffer | |
| EP3319984C0 (en) | TAU LINKING ANTIBODIES | |
| IL252354A0 (en) | Novel pd-l1 binding polypeptides for imaging | |
| DK3242892T3 (da) | Modificerede april-bindende antistoffer | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| DK3177646T3 (da) | Cd3-bindingsdomæne | |
| DK3191517T3 (da) | Krydsreaktive siglec-antistoffer | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| LT3556777T (lt) | Daugiaspecifiniai antikūno konstruktai | |
| DK3149042T3 (da) | PD-L1-antistoffer og anvendelser deraf | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| IL291164A (en) | Anti-nme antibody | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| LT3166970T (lt) | Patobulinti a-beta protofibriles surišantys antikūnai | |
| PL3215530T3 (pl) | Ulepszone przeciwciała anty-il-6 | |
| LT3092003T (lt) | Naujas anti-netrino-1 antikūnas |